Product
ALFQ
5 clinical trials
6 indications
Indication
HIV-1 infectionIndication
HIVIndication
HIV InfectionsIndication
PLWHIndication
Antiretroviral TherapyIndication
Acute HIV InfectionClinical trial
Safety and Efficacy of Broadly Neutralizing Antibodies Followed by Innate Immune Stimulation and Therapeutic Vaccination for the Induction of HIV RemissionStatus: Withdrawn, Estimated PCD: 2025-07-01
Clinical trial
Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy AdultsStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized, Double Blind Evaluation of Late Boost Strategies With IHV01 (FLSC in Aluminum Phosphate) and A244 With or Without ALFQ for HIV-uninfected Participants in the HIV Vaccine Trial RV306 / WRAIR 1920Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of ALFQ Adjuvant in a Candidate HIV Vaccine Containing A244 and B.65321Status: Recruiting, Estimated PCD: 2023-10-23
Clinical trial
Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for the Induction of HIV RemissionStatus: Not yet recruiting, Estimated PCD: 2027-08-01